Karl Landsteiner University Researches Durvalumab's Impact on Biliary Tract Cancer

Researchers at Karl Landsteiner University (klü) have explored the efficacy of durvalumab, an immunotherapy drug, in treating biliary tract cancer (BTC). The study's findings are based on the TOPAZ-1 trial.

The investigation focused on durvalumab in combination with platinum and gemcitabine. The researchers demonstrated that this combination proves effective in real-world clinical practice. The treatment regimen was shown to improve both the time to disease progression and patient survival.

Hossein Taghizadeh, a researcher at klü, was among the authors of the study. The results were published open access in the journal Cancer Immunology, Immunotherapy. The research analyzed durvalumab's effects on patients with biliary tract cancer using real-world clinical data.

The findings suggest that durvalumab, when combined with chemotherapy, offers a significant benefit to patients with advanced biliary tract cancer. This discovery reinforces the role of immunotherapy in cancer treatment and opens new therapeutic avenues for this challenging disease.